Regen Biopharma settles ChemDiv lawsuit for $800k, contingent on SEC filing by Sept 24

Regen BioPharma Inc

Regen to pay $800k lump sum by Sept 30, 2021, to settle ChemDiv's breach-of-contract lawsuit over ~$1.2M unpaid invoices.
Settlement contingent on Regen filing acceptable SEC documents by Sept 24 to maintain listing status.
Upon payment, ChemDiv dismisses litigation with prejudice and transfers NR2F6 research data, compounds, and IP to Regen and Zander.
If payment not made by Sept 30, agreement void and litigation continues with trial set for Oct 29, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.